Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 2, 2016Seminars in Thrombosis and Hemostasis

Treatment of von Willebrand Disease

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with congenital von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS)

Design

Review

Authors

LPLeonardo PasalicThe University of SydneyEFEmmanuel J. FavaloroVascular MedicineJCJennifer CurnowThe University of Sydney

Discussion

Loading...

Member takes

Overview

VWF replacement remains first-line for VWD/AVWS bleeding prevention; leaves open optimal regimens and non-replacement strategies.

Structured PICO

P
Population
Patients with congenital von Willebrand disease (VWD) and acquired von Willebrand syndrome (AVWS)
I
Intervention
Replacement of von Willebrand factor (VWF) and/or factor VIII (FVIII) using concentrates, desmopressin, and adjunct therapies like antifibrinolytics
O
Outcome
Protection against bleeding

This review summarizes current standard-of-care treatments for von Willebrand disease, highlighting the primary role of VWF and FVIII replacement therapies to prevent bleeding.

Cite This Study

Pasalic et al. (2016) studied this question.

synapsesocial.com/papers/6a968c5896bab72bf50e2e0bhttps://doi.org/10.1055/s-0035-1569070
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting von Willebrand disease: the current status and future directions of management therapies2023 · 2 citations
  2. 2Treatment of patients with von Willebrand disease2011 · 16 citations
  3. 3Current Therapeutic Innovations in the Treatment of Von Willebrand Disease2025
  4. 4Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report2018 · 2 citations
  5. 5Therapeutic approaches to acquired von Willebrand syndrome2000 · 37 citations